The final session on cardiorenal anemia syndrome focuses on treatment strategies to improve patient outcomes. It covers intravenous iron formulations, their dosing, and indications, while emphasizing the importance of recognizing adverse drug reactions. A patient case study highlights the management of chronic kidney disease and heart failure. The session reviews guidelines for administering IV iron and discusses the safety and efficacy of FDA-approved products, including recent regulatory updates.